The administration of IL-21 and antibody-coated tumor cells leads to synergistic cytotoxic effects of NK cells toward tumor cells, which suggests that IL-21 may be an effective adjuvant for antibody treatment (214). The gene discussed is IL21; the disease is neoplasm.